In vitro echogenicity characterization of poly[lactide-coglycolide] (plga) microparticles and preliminary in vivo ultrasound enhancement study for ultrasound contrast agent application
- PMID: 16024992
- DOI: 10.1097/01.rli.0000170818.03210.ee
In vitro echogenicity characterization of poly[lactide-coglycolide] (plga) microparticles and preliminary in vivo ultrasound enhancement study for ultrasound contrast agent application
Abstract
Objectives: This work includes (1) the characterization of a reproducible poly[lactide-coglycolide] (PLGA) microparticle preparation with an optimial mean diameter and size distribution and (2) the preliminary in vivo ultrasonographic investigation of PLGA microparticles.
Methods: A first series of PLGA microparticle preparations (1 to 15 mum) was acoustically characterized on a hydrodynamic device to select the most appropriate for ultrasound contrast agent application. Preparations of 3-microm microparticles were selected, characterized at different doses, and then injected into 20 melanoma grafted mice for contrast-enhanced power Doppler ultrasonography evaluation.
Results: The 3-microm microparticles (3.26-microm mean diameter with 0.41-microm standard deviation) led to in vitro enhancement of 18.3 dB at 0.62 mg/mL. In vivo experiments showed 47% enhancement of intratumoral vascularization detection after PLGA injection, significantly correlated (P < 0.0001) with preinjection intravascularization and tumoral volume. No toxicity was histologically observed.
Conclusion: The 3-microm PLGA microparticles provided significant enhancement in vitro and in vivo without any toxicity.
Similar articles
-
Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres.Pharm Res. 2003 Mar;20(3):452-9. doi: 10.1023/a:1022668507748. Pharm Res. 2003. PMID: 12669968
-
Pharmaceutical evaluation of gas-filled microparticles as gene delivery system.Pharm Res. 2002 Mar;19(3):250-7. doi: 10.1023/a:1014430631844. Pharm Res. 2002. PMID: 11934230
-
A heterogeneously structured composite based on poly(lactic-co-glycolic acid) microspheres and poly(vinyl alcohol) hydrogel nanoparticles for long-term protein drug delivery.Pharm Res. 1999 Sep;16(9):1430-5. doi: 10.1023/a:1018911411381. Pharm Res. 1999. PMID: 10496661
-
[Advance in the study of poly(lactide-co-glycolide) nano/microparticles as gene vector].Yao Xue Xue Bao. 2010 Nov;45(11):1346-53. Yao Xue Xue Bao. 2010. PMID: 21361033 Review. Chinese.
-
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.Biomaterials. 2000 Dec;21(23):2475-90. doi: 10.1016/s0142-9612(00)00115-0. Biomaterials. 2000. PMID: 11055295 Review.
Cited by
-
Determination of the interfacial rheological properties of a poly(DL-lactic acid)-encapsulated contrast agent using in vitro attenuation and scattering.Ultrasound Med Biol. 2013 Jul;39(7):1277-91. doi: 10.1016/j.ultrasmedbio.2013.02.004. Epub 2013 May 1. Ultrasound Med Biol. 2013. PMID: 23643050 Free PMC article.
-
Current advances in research and clinical applications of PLGA-based nanotechnology.Expert Rev Mol Diagn. 2009 May;9(4):325-41. doi: 10.1586/erm.09.15. Expert Rev Mol Diagn. 2009. PMID: 19435455 Free PMC article. Review.
-
Magnetic resonance and ultrasound contrast imaging of polymer-shelled microbubbles loaded with iron oxide nanoparticles.R Soc Open Sci. 2016 Aug 3;3(8):160063. doi: 10.1098/rsos.160063. eCollection 2016 Aug. R Soc Open Sci. 2016. PMID: 27853587 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous